165 related articles for article (PubMed ID: 33378691)
1. NLRP1 variant M1184V decreases inflammasome activation in the context of DPP9 inhibition and asthma severity.
Moecking J; Laohamonthonkul P; Chalker K; White MJ; Harapas CR; Yu CH; Davidson S; Hrovat-Schaale K; Hu D; Eng C; Huntsman S; Calleja DJ; Horvat JC; Hansbro PM; O'Donoghue RJJ; Ting JP; Burchard EG; Geyer M; Gerlic M; Masters SL
J Allergy Clin Immunol; 2021 Jun; 147(6):2134-2145.e20. PubMed ID: 33378691
[TBL] [Abstract][Full Text] [Related]
2. Inflammasome sensor NLRP1 disease variant M1184V promotes autoproteolysis and DPP9 complex formation by stabilizing the FIIND domain.
Moecking J; Laohamonthonkul P; Meşe K; Hagelueken G; Steiner A; Harapas CR; Sandow JJ; Graves JD; Masters SL; Geyer M
J Biol Chem; 2022 Dec; 298(12):102645. PubMed ID: 36309085
[TBL] [Abstract][Full Text] [Related]
3. Human DPP9 represses NLRP1 inflammasome and protects against autoinflammatory diseases via both peptidase activity and FIIND domain binding.
Zhong FL; Robinson K; Teo DET; Tan KY; Lim C; Harapas CR; Yu CH; Xie WH; Sobota RM; Au VB; Hopkins R; D'Osualdo A; Reed JC; Connolly JE; Masters SL; Reversade B
J Biol Chem; 2018 Dec; 293(49):18864-18878. PubMed ID: 30291141
[TBL] [Abstract][Full Text] [Related]
4. DPP9 sequesters the C terminus of NLRP1 to repress inflammasome activation.
Hollingsworth LR; Sharif H; Griswold AR; Fontana P; Mintseris J; Dagbay KB; Paulo JA; Gygi SP; Bachovchin DA; Wu H
Nature; 2021 Apr; 592(7856):778-783. PubMed ID: 33731932
[TBL] [Abstract][Full Text] [Related]
5. DPP9 deficiency: An inflammasomopathy that can be rescued by lowering NLRP1/IL-1 signaling.
Harapas CR; Robinson KS; Lay K; Wong J; Moreno Traspas R; Nabavizadeh N; Rass-Rothschild A; Boisson B; Drutman SB; Laohamonthonkul P; Bonner D; Xiong JR; Gorrell MD; Davidson S; Yu CH; Fleming MD; Gudera J; Stein J; Ben-Harosh M; Groopman E; Shimamura A; Tamary H; Kayserili H; Hatipoğlu N; Casanova JL; Bernstein JA; Zhong FL; Masters SL; Reversade B
Sci Immunol; 2022 Sep; 7(75):eabi4611. PubMed ID: 36112693
[TBL] [Abstract][Full Text] [Related]
6. Structural and biochemical mechanisms of NLRP1 inhibition by DPP9.
Huang M; Zhang X; Toh GA; Gong Q; Wang J; Han Z; Wu B; Zhong F; Chai J
Nature; 2021 Apr; 592(7856):773-777. PubMed ID: 33731929
[TBL] [Abstract][Full Text] [Related]
7. Hemophagocytic lymphohistiocytosis-like hyperinflammation due to a de novo mutation in DPP9.
Wolf C; Fischer H; Kühl JS; Koss S; Jamra RA; Starke S; Schultz J; Ehl S; Neumann K; Schuetz C; Huber R; Hornung V; Lee-Kirsch MA
J Allergy Clin Immunol; 2023 Nov; 152(5):1336-1344.e5. PubMed ID: 37544411
[TBL] [Abstract][Full Text] [Related]
8. DPP8/DPP9 inhibition elicits canonical Nlrp1b inflammasome hallmarks in murine macrophages.
de Vasconcelos NM; Vliegen G; Gonçalves A; De Hert E; Martín-Pérez R; Van Opdenbosch N; Jallapally A; Geiss-Friedlander R; Lambeir AM; Augustyns K; Van Der Veken P; De Meester I; Lamkanfi M
Life Sci Alliance; 2019 Feb; 2(1):. PubMed ID: 30718379
[TBL] [Abstract][Full Text] [Related]
9. DPP8/9 inhibitors are universal activators of functional NLRP1 alleles.
Gai K; Okondo MC; Rao SD; Chui AJ; Ball DP; Johnson DC; Bachovchin DA
Cell Death Dis; 2019 Aug; 10(8):587. PubMed ID: 31383852
[TBL] [Abstract][Full Text] [Related]
10. DPP9's Enzymatic Activity and Not Its Binding to CARD8 Inhibits Inflammasome Activation.
Griswold AR; Ball DP; Bhattacharjee A; Chui AJ; Rao SD; Taabazuing CY; Bachovchin DA
ACS Chem Biol; 2019 Nov; 14(11):2424-2429. PubMed ID: 31525884
[TBL] [Abstract][Full Text] [Related]
11. KSHV-encoded ORF45 activates human NLRP1 inflammasome.
Yang X; Zhou J; Liu C; Qu Y; Wang W; Xiao MZX; Zhu F; Liu Z; Liang Q
Nat Immunol; 2022 Jun; 23(6):916-926. PubMed ID: 35618833
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for thioredoxin-mediated suppression of NLRP1 inflammasome.
Zhang Z; Shibata T; Fujimura A; Kitaura J; Miyake K; Ohto U; Shimizu T
Nature; 2023 Oct; 622(7981):188-194. PubMed ID: 37704723
[TBL] [Abstract][Full Text] [Related]
13. Methods to Activate the NLRP1 Inflammasome.
Gao H; Liu P; Dong N
Methods Mol Biol; 2023; 2696():211-222. PubMed ID: 37578725
[TBL] [Abstract][Full Text] [Related]
14. Autophagy in the HTR-8/SVneo Cell Oxidative Stress Model Is Associated with the NLRP1 Inflammasome.
Li M; Sun T; Wu X; An P; Wu X; Dang H
Oxid Med Cell Longev; 2021; 2021():2353504. PubMed ID: 33854691
[TBL] [Abstract][Full Text] [Related]
15. DPP9 restrains NLRP1 activation.
Bauernfried S; Hornung V
Nat Struct Mol Biol; 2021 Apr; 28(4):333-336. PubMed ID: 33785922
[No Abstract] [Full Text] [Related]
16. Dipeptidyl peptidase 9 sets a threshold for CARD8 inflammasome formation by sequestering its active C-terminal fragment.
Sharif H; Hollingsworth LR; Griswold AR; Hsiao JC; Wang Q; Bachovchin DA; Wu H
Immunity; 2021 Jul; 54(7):1392-1404.e10. PubMed ID: 34019797
[TBL] [Abstract][Full Text] [Related]
17. Frequency of Interleukins IL1ß/IL18 and Inflammasome NLRP1/NLRP3 Polymorphisms in Sickle Cell Anemia Patients and their Association with Severity Score.
de Almeida E; Frantz SR; Cesar P; Tarragô AM; de Amorim Xabregas L; Garcia NP; Costa AG; de Paula EV; Malheiro A
Curr Mol Med; 2019; 19(10):776-783. PubMed ID: 31448710
[TBL] [Abstract][Full Text] [Related]
18. Germline NLRP1 Mutations Cause Skin Inflammatory and Cancer Susceptibility Syndromes via Inflammasome Activation.
Zhong FL; Mamaï O; Sborgi L; Boussofara L; Hopkins R; Robinson K; Szeverényi I; Takeichi T; Balaji R; Lau A; Tye H; Roy K; Bonnard C; Ahl PJ; Jones LA; Baker PJ; Lacina L; Otsuka A; Fournie PR; Malecaze F; Lane EB; Akiyama M; Kabashima K; Connolly JE; Masters SL; Soler VJ; Omar SS; McGrath JA; Nedelcu R; Gribaa M; Denguezli M; Saad A; Hiller S; Reversade B
Cell; 2016 Sep; 167(1):187-202.e17. PubMed ID: 27662089
[TBL] [Abstract][Full Text] [Related]
19. Human NLRP1: From the shadows to center stage.
Bauernfried S; Hornung V
J Exp Med; 2022 Jan; 219(1):. PubMed ID: 34910085
[TBL] [Abstract][Full Text] [Related]
20. P38 kinases mediate NLRP1 inflammasome activation after ribotoxic stress response and virus infection.
Jenster LM; Lange KE; Normann S; vom Hemdt A; Wuerth JD; Schiffelers LDJ; Tesfamariam YM; Gohr FN; Klein L; Kaltheuner IH; Ebner S; Lapp DJ; Mayer J; Moecking J; Ploegh HL; Latz E; Meissner F; Geyer M; Kümmerer BM; Schmidt FI
J Exp Med; 2023 Jan; 220(1):. PubMed ID: 36315050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
